SCHEMBL25933969

SCHEMBL25933969

Cc1ccc(-c2nn(C3CCN(C4CNC4)CC3)c3ncnc(N)c23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 4/20 0.56
NUDT14 O95848 2/20 0.56
NUDT5 Q9UKK9 2/20 0.56
SRC P12931 14/20 0.56
KDR P35968 13/20 0.56
ABL1 P00519 11/20 0.56
EGFR P00533 11/20 0.56
MTOR P42345 11/20 0.56
PIK3CD O00329 11/20 0.56
PIK3CA P42336 11/20 0.56
PIK3CB P42338 11/20 0.56
PIK3CG P48736 11/20 0.56
PRKDC P78527 11/20 0.56
HCK P08631 10/20 0.56
PI4KB Q9UBF8 9/20 0.56
EPHB4 P54760 9/20 0.56
LCK P06239 6/20 0.55
TEK Q02763 4/20 0.55
IGF1R P08069 1/20 0.53
LYN P07948 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25933743 0.93 BTK (0.66) BTKNUDT14NUDT5SRCKDR
SCHEMBL25933729 0.91 BTK (0.62) BTKNUDT14NUDT5SRCKDR
SCHEMBL25933673 0.90 BTK (0.49) BTKNUDT14NUDT5SRCKDR
SCHEMBL24197215 0.86 BTK (0.66) BTKNUDT14NUDT5SRCKDR
SCHEMBL25933948 0.86 EGFR (0.50) BTKNUDT14NUDT5SRCKDR
SCHEMBL25933940 0.86 EGFR (0.50) BTKNUDT14NUDT5SRCKDR
SCHEMBL25933741 0.86 BTK (0.66) BTKNUDT14NUDT5SRCKDR
SCHEMBL24196861 0.86 BTK (0.66) BTKNUDT14NUDT5SRCKDR
SCHEMBL25933912 0.86 EGFR (0.50) BTKNUDT14NUDT5SRCKDR
SCHEMBL25933927 0.86 EGFR (0.50) BTKNUDT14NUDT5SRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230248833-A1 COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR BTK, WEE1, WEE2 BTK 1/4885NUDT14 3438/4885NUDT5 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.